These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 11108629)

  • 1. Quantitative gadopentetate-enhanced MRI of breast tumors: testing of different analytic methods.
    Helbich TH; Roberts TP; Gossmann A; Wendland MF; Shames DM; Adachi M; Yang S; Huber S; Daldrup H; Brasch RC
    Magn Reson Med; 2000 Dec; 44(6):915-24. PubMed ID: 11108629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media.
    Daldrup H; Shames DM; Wendland M; Okuhata Y; Link TM; Rosenau W; Lu Y; Brasch RC
    AJR Am J Roentgenol; 1998 Oct; 171(4):941-9. PubMed ID: 9762973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Gadomer-17 and gadopentetate dimeglumine for differentiation of benign from malignant breast tumors with MR imaging.
    Daldrup-Link HE; Shames DM; Wendland M; Mühler A; Gossmann A; Rosenau W; Brasch RC
    Acad Radiol; 2000 Nov; 7(11):934-44. PubMed ID: 11089696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of dynamic contrast-enhanced magnetic resonance imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media.
    Daldrup H; Shames DM; Wendland M; Okuhata Y; Link TM; Rosenau W; Lu Y; Brasch RC
    Pediatr Radiol; 1998 Feb; 28(2):67-78. PubMed ID: 9472047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MRI tumor characterization using Gd-GlyMe-DOTA-perfluorooctyl-mannose-conjugate (Gadofluorine M), a protein-avid contrast agent.
    Raatschen HJ; Swain R; Shames DM; Fu Y; Boyd Z; Zierhut ML; Wendland MF; Misselwitz B; Weinmann HJ; Wolf KJ; Brasch RC
    Contrast Media Mol Imaging; 2006; 1(3):113-20. PubMed ID: 17193687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macromolecular contrast media-enhanced MRI estimates of microvascular permeability correlate with histopathologic tumor grade.
    Brasch RC; Daldrup H; Shames D; Wendland M; Okuhata Y; Rosenau W
    Acad Radiol; 1998 Apr; 5 Suppl 1():S2-5. PubMed ID: 9561030
    [No Abstract]   [Full Text] [Related]  

  • 7. Characterization of N-ethyl-N-nitrosourea-induced malignant and benign breast tumors in rats by using three MR contrast agents.
    Su MY; Wang Z; Carpenter PM; Lao X; Mühler A; Nalcioglu O
    J Magn Reson Imaging; 1999 Feb; 9(2):177-86. PubMed ID: 10077011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MR imaging characterization of microvessels in experimental breast tumors by using a particulate contrast agent with histopathologic correlation.
    Turetschek K; Huber S; Floyd E; Helbich T; Roberts TP; Shames DM; Tarlo KS; Wendland MF; Brasch RC
    Radiology; 2001 Feb; 218(2):562-9. PubMed ID: 11161179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic approach for dynamic breast MRI to indicate signal intensity time curves of benign and malignant lesions by using the tumor flow residence time.
    Renz DM; Diekmann F; Schmitzberger FF; Pietsch H; Fallenberg EM; Durmus T; Huppertz A; Böttcher J; Bick U; Hamm B; Lawaczeck R
    Invest Radiol; 2013 Feb; 48(2):69-78. PubMed ID: 23262793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI assessment of microvascular characteristics in experimental breast tumors using a new blood pool contrast agent (MS-325) with correlations to histopathology.
    Turetschek K; Floyd E; Helbich T; Roberts TP; Shames DM; Wendland MF; Carter WO; Brasch RC
    J Magn Reson Imaging; 2001 Sep; 14(3):237-42. PubMed ID: 11536400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The choice of region of interest measures in contrast-enhanced magnetic resonance image characterization of experimental breast tumors.
    Preda A; Turetschek K; Daldrup H; Floyd E; Novikov V; Shames DM; Roberts TP; Carter WO; Brasch RC
    Invest Radiol; 2005 Jun; 40(6):349-54. PubMed ID: 15905721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantification of blood flow in brain tumors: comparison of arterial spin labeling and dynamic susceptibility-weighted contrast-enhanced MR imaging.
    Warmuth C; Gunther M; Zimmer C
    Radiology; 2003 Aug; 228(2):523-32. PubMed ID: 12819338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast neoplasms: T2* susceptibility-contrast, first-pass perfusion MR imaging.
    Kuhl CK; Bieling H; Gieseke J; Ebel T; Mielcarek P; Far F; Folkers P; Elevelt A; Schild HH
    Radiology; 1997 Jan; 202(1):87-95. PubMed ID: 8988196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast lesions: evaluation with dynamic contrast-enhanced T1-weighted MR imaging and with T2*-weighted first-pass perfusion MR imaging.
    Kvistad KA; Rydland J; Vainio J; Smethurst HB; Lundgren S; Fjøsne HE; Haraldseth O
    Radiology; 2000 Aug; 216(2):545-53. PubMed ID: 10924584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of a rapid clearance blood pool MR contrast medium (P792) for assays of microvascular characteristics in experimental breast tumors with correlations to histopathology.
    Turetschek K; Floyd E; Shames DM; Roberts TP; Preda A; Novikov V; Corot C; Carter WO; Brasch RC
    Magn Reson Med; 2001 May; 45(5):880-6. PubMed ID: 11323815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic contrast-enhanced magnetic resonance imaging evaluation of VX2 carcinoma in a rabbit model: comparison of 1.0-M gadobutrol and 0.5-M gadopentetate dimeglumine.
    Chang JM; Moon WK; Cha JH; Jung EJ; Cho N; Kim SJ
    Invest Radiol; 2010 Oct; 45(10):655-61. PubMed ID: 20808238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteosarcoma: preliminary results of in vivo assessment of tumor necrosis after chemotherapy with diffusion- and perfusion-weighted magnetic resonance imaging.
    Uhl M; Saueressig U; van Buiren M; Kontny U; Niemeyer C; Köhler G; Ilyasov K; Langer M
    Invest Radiol; 2006 Aug; 41(8):618-23. PubMed ID: 16829744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-dimensional contrast enhanced ultrasound score and dynamic contrast-enhanced magnetic resonance imaging score in evaluating breast tumor angiogenesis: correlation with biological factors.
    Jia WR; Chai WM; Tang L; Wang Y; Fei XC; Han BS; Chen M
    Eur J Radiol; 2014 Jul; 83(7):1098-1105. PubMed ID: 24794865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying tumor vascular permeability heterogeneity with magnetic resonance imaging contrast agents.
    Aref M; Brechbiel M; Wiener EC
    Invest Radiol; 2002 Apr; 37(4):178-92. PubMed ID: 11923640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-Molecular-Weight Iron Chelates May Be an Alternative to Gadolinium-based Contrast Agents for T1-weighted Contrast-enhanced MR Imaging.
    Boehm-Sturm P; Haeckel A; Hauptmann R; Mueller S; Kuhl CK; Schellenberger EA
    Radiology; 2018 Feb; 286(2):537-546. PubMed ID: 28880786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.